

CONTENTS

ENVIRONMENTAL HEALTH CRITERIA FOR *BACILLUS THURINGIENSIS*

PREAMBLE	vii
ABBREVIATIONS	xv
1. SUMMARY	1
1.1 Identity, biological characteristics, and analytical methods	1
1.2 Mode of action on target insects	2
1.3 Habitats	2
1.4 Commercial products, production and application	3
1.5 Effects of Bt on non-target organisms	3
1.6 Exposure and effects of Bt on humans	4
1.7 Conclusions	4
2. IDENTITY, BIOLOGICAL PROPERTIES, AND ANALYTICAL METHODS	6
2.1 Identity	6
2.1.1 <i>Bacillus thuringiensis</i> (Bt)	6
2.1.2 Relationship between <i>Bacillus thuringiensis</i> and <i>Bacillus cereus</i>	6
2.1.3 Crystal composition and morphology	7
2.1.4 Classification of Bt subspecies	8
2.1.5 Genetics of ICP	10
2.1.6 Beta-exotoxin	14
2.1.7 Other Bt metabolites	17
2.2 Bioassays	18
2.2.1 Spore counts	18
2.2.2 International bioassay for ICPs	18
3. MODE OF ACTION ON TARGET INSECTS	19
3.1 Bioactivity of field isolates	19
3.2 Mechanism of action of Bt formulations	19

3.3.	Resistance of insect populations	21
4.	NATURAL AND TREATED HABITATS	23
4.1	Natural occurrence of Bt	23
4.1.1	Bt in insect hosts	23
4.1.2	Bt in soil	24
4.1.3	Bt on plant surfaces	24
4.2	Treated habitats	25
4.3	Environmental fate, distribution and movement	25
4.3.1	Distribution and fate of Bt in terrestrial habitats	26
4.3.1.1	Fate of Bt and ICP on plant surfaces	26
4.3.1.2	Fate of Bt in soil	27
4.3.2	Distribution and fate of Bt in aquatic habitats	29
4.3.3	Transport of Bt by non-target organisms	30
5.	COMMERCIAL PRODUCTION	31
5.1	History of Bt and its commercial applications	31
5.1.1	Production levels	31
5.1.2	Production processes, formulations and quality standards	31
5.1.3	General patterns of use	32
5.1.3.1	Applications in agriculture and forestry	32
5.1.3.2	Applications in vector control	34
6.	EFFECTS ON ANIMALS	36
6.1	Mammals	36
6.1.1	Oral exposure	37
6.1.2	Inhalation exposure	39
6.1.3	Dermal exposure	39
6.1.4	Dermal scarification exposure	40
6.1.5	Subcutaneous inoculation	40
6.1.6	Ocular exposure	40
6.1.7	Intraperitoneal exposure	41
6.1.7.1	Immune-intact animals	43

	6.1.7.2	Immune-suppressed animals	44
	6.1.8	Effects of activated Bt ICP	45
	6.1.9	Studies in wild animals	45
6.2		Effects on birds	45
6.3		Effects on aquatic vertebrates	47
6.4		Effects on invertebrates	49
	6.4.1	Effects on invertebrates other than insects .	49
	6.4.2	Effects on non-target insects	50
	6.4.2.1	Aquatic insects	50
	6.4.2.2	Terrestrial insects	54
	6.4.2.3	Honey-bees	59
	6.4.2.4	Parasitoids	60
7.		EXPOSURE AND EFFECTS ON HUMANS	63
	7.1	<i>Bacillus thuringiensis</i>	63
	7.1.1	Experimental exposure of humans	63
	7.1.2	Exposure of workers during manufacture . .	64
	7.1.3	Exposure of workers in spraying operations	64
	7.1.4	Exposure of human populations by spraying operations over populated areas.	65
	7.1.5	Clinical case reports	65
	7.1.6	Dietary exposure of the general population .	66
	7.2	<i>Bacillus cereus</i>	67
8.		EVALUATION OF HUMAN HEALTH RISKS AND EFFECTS ON THE ENVIRONMENT	69
9.		CONCLUSIONS AND RECOMMENDATIONS	70
10.		PREVIOUS EVALUATIONS BY INTERNATIONAL ORGANISATIONS	71
		REFERENCES	72
		RÉSUMÉ	94
		RESUMEN	100